Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Moodys
Daiichi Sankyo
Merck
Covington
Mallinckrodt
Fish and Richardson
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,709,022

« Back to Dashboard

Which drugs does patent 7,709,022 protect, and when does it expire?

Patent 7,709,022 protects CIPRO XR and is included in one NDA.

Protection for CIPRO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in forty countries.
Summary for Patent: 7,709,022
Title:Sustained-release preparations of quinolone antibiotics and method for preparation thereof
Abstract:The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
Inventor(s): Kanikanti; Venkata-Rangarao (Leverkusen, DE), Rupp; Roland (Bergisch Gladbach, DE), Weber; Wolfgang (Koln, DE), Deuringer; Peter (Koln, DE), Henck; Jan-Olav (Willich, DE), Sta.beta.; Heino (Koln, DE), Nishioka; Takaaki (Nabari, JP), Katakawa; Yoshifumi (Kusatsu, JP), Taniguchi; Chika (Nishinomiya, JP), Ichihashi; Hitoshi (Suita, JP)
Assignee: Bayer Schering Pharma AG (Leverkussen, DE)
Application Number:10/311,913
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,709,022
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 7,709,022

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-001 Dec 13, 2002 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-002 Aug 28, 2003 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,709,022

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 31 043Jun 26, 2000
PCT Information
PCT FiledJune 13, 2001PCT Application Number:PCT/EP01/06695
PCT Publication Date:January 03, 2002PCT Publication Number: WO02/00219

Non-Orange Book US Patents Family Members for Patent 7,709,022

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,780,986 Method of preparing sustained-release preparations of quinolone antibiotics ➤ Sign Up
8,187,632 Sustained-release preparations of quinolone antibiotics ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Mallinckrodt
Deloitte
Dow
Harvard Business School
UBS
Teva
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.